GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Results] 87 weeks, 36kg, and endpoint was the hard part — 27 comments in the full submission. View in context.
336
c/trialwatch·submitted 3 months ago by u/prior_auth_pain

[Results] 87 weeks, 36kg, and endpoint was the hard part

Press Releasebranch of 7 comments

STEP. That is the whole post, but I will justify it. Everything else people worry about in c/orforglipron is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort STEP out first, and almost nobody does. I say this having got it wrong for 23 months. My…

Read the full submission and all 27 comments →

This branch

7 comments, started 2 months ago
u/niels_norgaard25 points·2 months ago

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

replysharereportpermalink
u/receipts_or_nothingvetting6 points·2 months ago

the discontinuation arms are the interesting part, not the FLOW endpoints

replysharereportpermalink
u/anders_kuusela5 points·2 months ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink
u/adaeze_cabrera3 points·2 months ago

Small correction: the trial was 13 weeks, not 32. Does not change your point but people will quote it.

replysharereportpermalink
u/prior_auth_painOPappeals3 points·2 months ago

press release SURMOUNT posts must be flaired until a publication exists

replysharereportpermalink
u/piotr_bruun2 points·2 months ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/ewan_tulloch6 points·2 months ago

Phase 2 TRIUMPH looked amazing.

Yes, exactly this, and it is the bit that took me 28 weeks to accept.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →